News


SpA-Net awarded prize for best electronic patient file in rheumatology

At the “Najaarsdagen 2016”, the yearly conference of the Dutch Rheumatology Association (NVR), SpA-Net was awarded the prize for best electronic patient file in rheumatology. SpA-Net monitors the treatment outcomes and quality of care for patients with spondyloarthritis or psoriatic arthritis. Dr. Astrid van Tubergen, one of its initiators, received the prize on behalf of SpA-Net.

Oct 12, 2016


The DREAM registry as best practice for real life monitoring of expensive medications

The September issue of De Medisch Specialist (The Medical Specialist) featured an article about the DREAM registry as a best case example of how the real life efficacy and possible side effects of expensive drugs can be monitored. Download the article (in Dutch) here.

Sep 16, 2016


Minister Schippers calls the DREAM registry an example for transparency in health care outcomes

2015 was declared to be the year of transparency by Minister Schippers (Ministry of Health, Welfare and Sport). In a recent letter to the House of Representatives, the minister describes the most important results of this initiative. In this letter, she emphasizes the importance of measuring outcomes that matter to patients. The DREAM collaboration is specifically mentioned as an example of how outcomes measurement and transparency lead to improved quality of healthcare and patient empowerment. Download the letter here (DREAM is mentioned on page 4).

Sep 7, 2016


POET study in the media

The results of the POET study are increasingly being picked up by the media. Read some of the items about the study here:

General information about the study can be found at ReumaZorg Nederland.

Apr 7, 2016


Substantial increase in adverse reactions reported to Lareb

According to Lareb the number of centrally reported adverse events increased by 11% in 2015, partly due to the automated forwarding of events by the DREAM registry.

Lareb is the official Netherlands Pharmacovigilance Centre responsible for collecting and analyzing reports of adverse reactions of medicines and vaccines. In 2015, Lareb and the DREAM registry started a collaboration to improve the reporting and analysis of adverse reaction in patients with rheumatic conditions.   

In Mijnreumacentrum, the online monitoring system of DREAM, all adverse reactions are now automatically forwarded to the central collection point of Lareb. Here, the events are coded according to the MedDRA system, stored in their central database, and returned to the DREAM database.  

In their Highlights 2015 report, Lareb reports that the number of centrally collected adverse reactions increased by 11% in 2015. The number of events reported by healthcare professionals increased for the first time in years, according to Lareb mostly because of this new collaboration.

Apr 7, 2016